Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
NICE has recommended tebentafusp as an option for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company provides it according to the commercial arrangement.
Eligible population for tebentafusp
Table 1 shows the population who are eligible for tebentafusp and the number of people who are expected to have tebentafusp in each of the next 5 years.
| Eligible population and uptake | Current practice | 2025-26 | 2026-27 | 2027-28 | 2028-29 | 2029-30 |
|---|---|---|---|---|---|---|
|
People eligible for tebentafusp (rounded to nearest 5) |
120 |
120 |
120 |
120 |
125 |
125 |
|
Uptake for tebentafusp (%) |
0 |
25 |
50 |
50 |
50 |
50 |
|
People having tebentafusp each year (rounded to nearest 5) |
0 |
30 |
60 |
60 |
60 |
60 |
The market share for tebentafusp is based on projections from the manufacturer and NHS England.
Treatment options for the eligible population
The other treatment for the eligible population is pembrolizumab.
Both tebentafusp and pembrolizumab are administered intravenously, but tebentafusp has more administrations. In addition, the first 3 administrations of tebentafusp require admission to hospital and 16 hours of monitoring.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The company has a commercial arrangement. This makes tebentafusp available to the NHS with a discount.
Users can input the confidential price of tebentafusp and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Table 2 shows the impact on capacity activity in each of the next 5 years.
| Capacity impact | Current practice | 2025-26 | 2026-27 | 2027-28 | 2028-29 | 2029-30 |
|---|---|---|---|---|---|---|
|
Number of administration appointments |
950 |
1,680 |
2,430 |
2,450 |
2,470 |
2,500 |
|
Number of tests (rounded to nearest 5) |
0 |
320 |
320 |
325 |
330 |
330 |
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 Days |
|---|---|
| Programme budgeting category |
02E cancer, skin |
| Commissioner |
NHS England |
| Provider |
NHS hospital trusts |
| Pathway position |
First line |
About this resource impact summary report
This resource impact summary report accompanies the NICE guidance on Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma and should be read with it. See terms and conditions and on the NICE website.
ISBN: 978-1-4731-6774-2